Stage
|
Stage IIB/C
|
1.52
|
(1.44,1.60)
|
<.0001
|
Stage IIIA
|
1.00
|
–
|
–
|
Age
|
18–49
|
–
|
–
|
–
|
50–64
|
1.24
|
(1.06, 1.44)
|
0.006
|
65–74
|
1.70
|
(1.44, 1.99)
|
<.0001
|
75 and more
|
2.85
|
(2.43, 3.35)
|
<.0001
|
Race/Ethnicity
|
White
|
1.00
|
–
|
–
|
Black
|
1.18
|
(1.09, 1.28)
|
<.0001
|
American Indian, Aleutian, or Eskimo
|
1.15
|
(0.71, 1.87)
|
0.57
|
Asian or Pacific Islander
|
0.76
|
(0.62, 0.94)
|
0.01
|
Other
|
0.73
|
(0.45, 1.18)
|
0.20
|
Facility Type
|
Community cancer program
|
1.29
|
(1.18, 1.40)
|
<.0001
|
Comprehensive community cancer center
|
1.15
|
(1.08, 1.22)
|
<.0001
|
Academic research program
|
1.00
|
–
|
–
|
Facility Location
|
New England
|
1.00
|
(0.88, 1.14)
|
0.98
|
Mid Atlantic
|
0.99
|
(0.90, 1.10)
|
0.91
|
South Atlantic
|
0.95
|
(0.87, 1.05)
|
0.32
|
East North Central
|
0.95
|
(0.87, 1.05)
|
0.31
|
East South Central
|
0.98
|
(0.87, 1.11)
|
0.79
|
West North Central
|
1.02
|
(0.91, 1.15)
|
0.68
|
West South Central
|
0.96
|
(0.85, 1.08)
|
0.46
|
Mountain
|
0.91
|
(0.79, 1.06)
|
0.25
|
Pacific
|
1.00
|
–
|
–
|
Urban/Rural Location
|
Metro ≥1 million
|
1.00
|
–
|
–
|
Metro 250 k to 1 million
|
1.02
|
(0.96, 1.08)
|
0.56
|
Urban <250 k
|
0.95
|
(0.87, 1.03)
|
0.22
|
Urban ≥ 20 k adjacent metro
|
0.98
|
(0.87, 1.11)
|
0.75
|
Urban ≥ 20 k not adjacent metro
|
0.89
|
(0.73, 1.08)
|
0.24
|
Urban <20 k adjacent metro
|
0.98
|
(0.87, 1.10)
|
0.68
|
Urban <20 k not adjacent metro
|
1.10
|
(0.94, 1.28)
|
0.25
|
Rural <2500 adjacent metro
|
0.93
|
(0.72, 1.21)
|
0.57
|
Rural <2500 not adjacent metro
|
0.90
|
(0.71, 1.14)
|
0.38
|
Comorbidities
|
0
|
1.00
|
–
|
–
|
1
|
1.26
|
(1.19, 1.33)
|
<.0001
|
2
|
1.65
|
(1.53, 1.77)
|
<.0001
|
Primary Site
|
Cecum
|
1.00
|
–
|
–
|
Ascending Colon
|
1.00
|
(0.93, 1.08)
|
0.99
|
Hepatic Flexure
|
1.02
|
(0.90, 1.16)
|
0.72
|
Transverse Colon
|
0.97
|
(0.88, 1.06)
|
0.45
|
Splenic Flexure
|
1.16
|
(0.99, 1.35)
|
0.07
|
Descending Colon
|
1.06
|
(0.95, 1.19)
|
0.31
|
Sigmoid Colon
|
0.98
|
(0.92, 1.05)
|
0.58
|
Overlapping Lesions
|
0.92
|
(0.70, 1.20)
|
0.54
|
Not Otherwise Specified
|
1.39
|
(1.17, 1.66)
|
0.0002
|
Readmission within 30 days of Surgery
|
Not readmitted
|
1.00
|
–
|
–
|
Readmitted
|
1.21
|
(1.12, 1.31)
|
<.0001
|
Grade
|
Well differentiated
|
1.00
|
–
|
–
|
Moderately differentiated
|
1.07
|
(0.98, 1.16)
|
0.12
|
Poorly differentiated
|
1.20
|
(1.09, 1.32)
|
0.0002
|
Undifferentiated, anaplastic
|
1.21
|
(1.00, 1.47)
|
0.05
|
Regional Lymph Nodes Examined
|
0–11
|
1.30
|
(1.23, 1.37)
|
<.0001
|
12–90
|
1.00
|
–
|
–
|
Chemotherapy
|
Yes
|
1.00
|
–
|
–
|
No
|
2.24
|
(2.11, 2.37)
|
<.0001
|
Surgical Margins
|
No residual tumor
|
1.00
|
–
|
–
|
With Residual tumor
|
1.56
|
(1.29, 1.89)
|
0.003
|